《中国康复理论与实践》

《中国康复理论与实践》 ›› 2008, Vol. 14 ›› Issue (02): 150-151.

• 基础研究 • 上一篇    下一篇

乳腺癌组织突变型BRCA2的表达及其临床康复意义探讨

孔萌萌; 陆东东; 陈宇星   

  1. 同济大学医学部生命科学与技术学院,上海市 200092
  • 收稿日期:2007-08-23 出版日期:2008-02-01 发布日期:2008-02-01

Expression of Mutant BRCA2 in Human Breast Cancer Tissue and Its Clinic-healing Significance

KONG Meng-meng, LU Dong-dong, CHEN Yu-xing.   

  1. Tongji University School of Life Science and Technology, Shanghai 200092, China
  • Received:2007-08-23 Published:2008-02-01 Online:2008-02-01

PDF (PC)

被引次数

1

摘要： 目的研究突变型BRCA2在人类乳腺癌组织中的表达及其临床康复意义。方法采用免疫荧光染色技术检测66例手术切除的乳腺癌组织及其癌旁组织中,突变型BRCA2的表达及其与患者临床康复因子间的相关性。结果66例乳腺癌患者的标本中,87.8%(58/66)突变型BRCA2表达上调;12.2%(8/66)肿瘤组织突变型BRCA2表达无显著改变;临床分期越晚与肿瘤分化程度越差者突变型BRCA2的表达指数(LI)值越大;硬癌与浸润癌类型患者突变型BRCA2的LI值较大;有癌转移患者突变型BRCA2的LI值显著高于无转移患者。结论突变型BRCA2的LI与乳腺癌患者的康复因子,如临床分期、肿瘤分化程度、肿瘤病理类型以及有无转移呈显著相关,且突变型BRCA2过表达可能影响乳腺癌患者的康复治疗。

关键词: 突变型BRCA2, 乳腺癌, 免疫荧光染色

Abstract: Objective To investigate the expression of mutant BRCA2 gene in human breast cancer tissue and its clinic-healing significance.Methods The expression of mutant BRCA2 gene in breast cancer tissues and adjacent non-cancerous tissues of 66 patients' samples was detected using immunofluorostainning(IFS)and the correlation between the expression of mutant BRCA2 and patient's clinic-pathological characteristic was analyzed.Results Among 66 patients' samples,87.8%(58/66)were up-regulated expression of mutant BRCA2 protein in breast cancer tissues and 12.2%(8/66)was no significant difference of the mutant BRCA2 expression between the cancer tissue and its corresponding adjacent noncancerous tissues.The label index(LI)of mutant BRCA2 gene was higher in the cases of breast carcinoma's later clinical stage,poor tumor differentiation grade,breast scirrhus carcinomas,infiltrative breast carcinomas and metastasis.Conclusion The overexpression of mutant BRCA2 gene in human breast cancer tissue is positively related to the breast carcinoma's clinical stage,tumor differentiation grade,the tumor pathological type and metastasis,and it may influence the healing therapy of the breast cancer patients.

Key words: mutant BRCA2, human breast cancer, immunofluorostainning